Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder

References

• Wyatt RJ, Henter I. An economic evaluation of manic-depressive illness – 1991. Soc. Psychiatry Psychiatr. Epidemiol.30(5), 213–219 (1995).
   PubMed Web of Science ®Google Scholar
• Bowden CL. Bipolar disorder and work loss. Am. J. Manag. Care11(Suppl. 3), S91–S94 (2005).
   Google Scholar
• Judd LL, Akiskal HS, Schettler PJ et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch. Gen. Psychiatry62(12), 1322–1330 (2005).
   PubMed Web of Science ®Google Scholar
• Ten Have M, Vollenberg W, Bijl R, Nolen WA. Bipolar disorder in the general population in The Netherlands (prevalence, consequences and care utilisation): results from The Netherlands Mental Survey and Incidence Study (NEMESIS). J. Affect. Disord.68, 203–213 (2002).
   PubMed Web of Science ®Google Scholar
• Nolen WA, Knoppert-van der Klein EAM, Hunig A et al.Guidelines on Bipolar disorders (In Dutch: Richtlijn bipolaire stoornissen). Nolen WA, Knoppert-van der Klein EAM, Hunig A et al. (Eds), Boom, Amsterdam, The Netherlands (2001).
   Google Scholar
• Vieta E, Goikolea JM. Atypical antipsychotics: newer options for mania and maintenance therapy. Bipolar Disord.7(Suppl. 4), 21–33 (2005).
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Brecher M, Paulsson B, Huizar K, Mullen J. Quetiapine or haloperidol as monotherapy for bipolar mania – a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur. Neuropsychopharmacol.15(5), 573–585 (2005).
   PubMed Web of Science ®Google Scholar
• Bowden CL, Grunze H, Mullen J et al. A randomized, double-blind, placebo-controlled efficay and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J. Clin. Psychiatry66(1), 111–121 (2005).
   PubMed Web of Science ®Google Scholar
• Vieta E, Mullen J, Brecher M, Paulsson B, Jones M. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double-blind, placebo-controlled studies. Curr. Med. Res. Opin.21(6), 923–934 (2005).
   PubMed Web of Science ®Google Scholar
• Sachs G, Chengappa KNR, Suppes T et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomised, double-blind, placebo controlled study. Bipolar Disord.6, 213–223 (2004).
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Trial 5077IL/0100 Clinical Study Report. A international multicenter, double-blind, randomized, placebo-controlled trial of safety and efficacy of SEROQUEL™ (quetiapine fumerate) as add-on therapy with lithium or divalproex in the treatment of acute mania. December 2002. Data on file.
   Google Scholar
• Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J. Clin. Psychopharmacol.24(6), 599–606 (2004).
   PubMed Web of Science ®Google Scholar
• Bijl RV, van Zessen G, Ravelli A. The Netherlands Mental Health Survey and Incidence Study (NEMESIS) objectives and design. Soc. Psychiatry Psychiatr. Epidemiol.33, 581–586 (1998).
   PubMed Web of Science ®Google Scholar
• de Graaf R, Bijl RV, Beekman ATF, Vollebergh WAM. Temporal sequencing of lifetime mood disorders in relation to co morbid anxiety and substance use disorders; findings from The Netherlands Mental Health Survey and Incidence Study. Soc. Psychiatry Psychiatr. Epidemiol.38, 1–11 (2003).
   PubMed Web of Science ®Google Scholar
• Banks J, Carson JS, Nelson BL. Discrete Event System Simulation. Englewood Cliffs, NJ, USA (1996).
   Google Scholar
• Weinstein MC, O’Brien B, Hornberger J et al. ISPOR Task Force on Good Research Practices – Modelling Studies. Principles of good practice for decision analytic modelling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices – Modelling Studies. Value Health6(1), 9–17 (2003).
   PubMed Web of Science ®Google Scholar
• Caro JJ.Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics23(4), 323–332 (2005).
   PubMed Web of Science ®Google Scholar
• Young RC, Biggs JT, Ziegler VE et al. A rating scale for mania: reliability, validity, and sensitivity. Br. J. Psychiatry133, 429–435 (1978).
   PubMed Web of Science ®Google Scholar
• Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH (Eds). Insurance. Dutch Manual on Costing in Economic Evaluations, methods and standard prices for economic evaluations in health care. Foundation for Health Care, Amsterdam, The Netherlands (2004).
   Google Scholar
• Tariffbook Medical Specialists (In Dutch: Tariefboek medisch specialisten). College Tarieven Gezondheidszorg, Utrecht, The Netherlands (1999)
   Google Scholar
• Jaffe A, Levine J. Antipsychotic medication co prescribing in a large state hospital system. Pharmacoepidemiol. Drug Saf.12, 41–48 (2003).
   PubMed Web of Science ®Google Scholar
• Strakowski S, DelBello M, Adler C. Comparative efficacy and tolerability of drug treatments for bipolar disorder. CNS Drugs15(9), 701–718 (2001).
   PubMed Web of Science ®Google Scholar
• Namjoshi MA, Rajamannar G, Jacobs T et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J. Affect. Disord.69(1–3), 109–18 (2002).
   PubMed Web of Science ®Google Scholar
• Namjoshi MA, Risser R, Shi L, Tohen M, Breier A. Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid. J. Affect. Disord.81(3), 223–229 (2004).
   PubMedGoogle Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects, a comprehensive literature review. CNS Drugs19(Suppl. 1), 1–93 (2005).
   PubMed Web of Science ®Google Scholar
• Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia. Drugs64(20), 2291–2314 (2004).
   PubMed Web of Science ®Google Scholar
• Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann. Clin. Psychiatry14(3), 163–173 (2002).
   PubMedGoogle Scholar
• Tandon R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare? Psychiatr. Q.73(4), 297–311 (2002).
   PubMed Web of Science ®Google Scholar
• Perlis RH. The role of pharmacologic treatment guidelines for bipolar disorder. J. Clin. Psychiatry66(S3), 37–47 (2005).
   PubMedGoogle Scholar
• McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J. Clin. Psychiatry66(S3), 28–36 (2005).
   PubMed Web of Science ®Google Scholar
• Pini S, Abelli M, Cassano GB. The role of quetiapine in the treatment of bipolar disorder. Expert Opin. Pharmacother.7(7), 929–940 (2006).
   PubMed Web of Science ®Google Scholar